Amylyx Pharmaceuticals (AMLX) to Release Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Amylyx Pharmaceuticals to post earnings of ($0.53) per share for the quarter.

Amylyx Pharmaceuticals Trading Down 1.1 %

Shares of NASDAQ AMLX opened at $3.52 on Thursday. The firm has a 50 day moving average of $3.74 and a 200 day moving average of $3.77. The firm has a market capitalization of $241.30 million, a price-to-earnings ratio of -0.92 and a beta of -0.54. Amylyx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $19.95.

Insider Transactions at Amylyx Pharmaceuticals

In related news, CEO Justin B. Klee sold 7,471 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $4.04, for a total value of $30,182.84. Following the sale, the chief executive officer now owns 3,176,788 shares in the company, valued at approximately $12,834,223.52. The trade was a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Joshua B. Cohen sold 11,851 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $3.47, for a total transaction of $41,122.97. Following the completion of the sale, the chief executive officer now owns 3,201,247 shares in the company, valued at $11,108,327.09. This represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,000 shares of company stock valued at $84,142. 11.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AMLX. Bank of America upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $4.20 to $10.00 in a research report on Wednesday, October 23rd. Baird R W upgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $3.00 to $11.00 in a research report on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a report on Thursday, December 5th. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.